183 related articles for article (PubMed ID: 21476958)
1. Histamine H(3) receptor (H(3)R) antagonists and inverse agonists in the treatment of sleep disorders.
Broderick M; Masri T
Curr Pharm Des; 2011; 17(15):1426-9. PubMed ID: 21476958
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in histamine H3 receptor antagonists/inverse agonists.
Łazewska D; Kieć-Kononowicz K
Expert Opin Ther Pat; 2010 Sep; 20(9):1147-69. PubMed ID: 20716022
[TBL] [Abstract][Full Text] [Related]
3. Histamine H
Ghamari N; Zarei O; Arias-Montaño JA; Reiner D; Dastmalchi S; Stark H; Hamzeh-Mivehroud M
Pharmacol Ther; 2019 Aug; 200():69-84. PubMed ID: 31028835
[TBL] [Abstract][Full Text] [Related]
4. Pitolisant for treating patients with narcolepsy.
Li S; Yang J
Expert Rev Clin Pharmacol; 2020 Feb; 13(2):79-84. PubMed ID: 31937172
[No Abstract] [Full Text] [Related]
5. The Discovery of LML134, a Histamine H3 Receptor Inverse Agonist for the Clinical Treatment of Excessive Sleep Disorders.
Troxler T; Feuerbach D; Zhang X; Yang CR; Lagu B; Perrone M; Wang TL; Briner K; Bock MG; Auberson YP
ChemMedChem; 2019 Jul; 14(13):1238-1247. PubMed ID: 30957954
[TBL] [Abstract][Full Text] [Related]
6. 3-(1'-Cyclobutylspiro[4H-1,3-benzodioxine-2,4'-piperidine]-6-yl)-5,5-dimethyl-1,4-dihydropyridazin-6-one (CEP-32215), a new wake-promoting histamine H3 antagonist/inverse agonist.
Hudkins RL; Gruner JA; Raddatz R; Mathiasen JR; Aimone LD; Marino MJ; Bacon ER; Williams M; Ator MA
Neuropharmacology; 2016 Jul; 106():37-45. PubMed ID: 26400408
[TBL] [Abstract][Full Text] [Related]
7. The evolution of histamine H₃ antagonists/inverse agonists.
Lebois EP; Jones CK; Lindsley CW
Curr Top Med Chem; 2011; 11(6):648-60. PubMed ID: 21261594
[TBL] [Abstract][Full Text] [Related]
8. Effects of betahistine at histamine H3 receptors: mixed inverse agonism/agonism in vitro and partial inverse agonism in vivo.
Gbahou F; Davenas E; Morisset S; Arrang JM
J Pharmacol Exp Ther; 2010 Sep; 334(3):945-54. PubMed ID: 20530654
[TBL] [Abstract][Full Text] [Related]
9. A robust and high-capacity [(35)S]GTPgammaS binding assay for determining antagonist and inverse agonist pharmacological parameters of histamine H(3) receptor ligands.
Miller TR; Baranowski JL; Estvander BR; Witte DG; Carr TL; Manelli AM; Krueger KM; Cowart MD; Brioni JD; Esbenshade TA
Assay Drug Dev Technol; 2008 Jun; 6(3):339-49. PubMed ID: 18593375
[TBL] [Abstract][Full Text] [Related]
10. Effect of a novel histamine subtype-3 receptor inverse agonist and modafinil on EEG power spectra during sleep deprivation and recovery sleep in male volunteers.
James LM; Iannone R; Palcza J; Renger JJ; Calder N; Cerchio K; Gottesdiener K; Hargreaves R; Murphy MG; Boyle J; Dijk DJ
Psychopharmacology (Berl); 2011 Jun; 215(4):643-53. PubMed ID: 21301819
[TBL] [Abstract][Full Text] [Related]
11. Several down, a few to go: histamine H3 receptor ligands making the final push towards the market?
Kuhne S; Wijtmans M; Lim HD; Leurs R; de Esch IJ
Expert Opin Investig Drugs; 2011 Dec; 20(12):1629-48. PubMed ID: 21992603
[TBL] [Abstract][Full Text] [Related]
12. Progress in the development of histamine H
Łażewska D; Kieć-Kononowicz K
Expert Opin Ther Pat; 2018 Mar; 28(3):175-196. PubMed ID: 29334795
[TBL] [Abstract][Full Text] [Related]
13. The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders.
Parmentier R; Anaclet C; Guhennec C; Brousseau E; Bricout D; Giboulot T; Bozyczko-Coyne D; Spiegel K; Ohtsu H; Williams M; Lin JS
Biochem Pharmacol; 2007 Apr; 73(8):1157-71. PubMed ID: 17288995
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic characterization of S 38093, a novel inverse agonist at histamine H3 receptors.
Sors A; Panayi F; Bert L; Favale D; Nosjean O; Audinot V; Arrang JM; Buisson B; Steidl E; Delbos JM; Huhtala T; Kontkanen O; Chollet AM; Casara P; Lestage P
Eur J Pharmacol; 2017 May; 803():11-23. PubMed ID: 28336400
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel steroidal histamine H
Ledneczki I; Tapolcsányi P; Gábor E; Éles J; Greiner I; Schmidt É; Némethy Z; Kedves RS; Balázs O; Román V; Lévay G; Mahó S
Bioorg Med Chem Lett; 2017 Oct; 27(19):4525-4530. PubMed ID: 28888822
[TBL] [Abstract][Full Text] [Related]
16. Histamine H3-receptor inverse agonists as novel antipsychotics.
Ito C
Cent Nerv Syst Agents Med Chem; 2009 Jun; 9(2):132-6. PubMed ID: 20021346
[TBL] [Abstract][Full Text] [Related]
17. In vivo pharmacological profile of S 38093, a novel histamine H3 receptor inverse agonist.
Panayi F; Sors A; Bert L; Martin B; Rollin-Jego G; Billiras R; Carrié I; Albinet K; Danober L; Rogez N; Thomas JY; Pira L; Bertaina-Anglade V; Lestage P
Eur J Pharmacol; 2017 May; 803():1-10. PubMed ID: 28315340
[TBL] [Abstract][Full Text] [Related]
18. Histamine H3 receptor antagonists go to clinics.
Sander K; Kottke T; Stark H
Biol Pharm Bull; 2008 Dec; 31(12):2163-81. PubMed ID: 19043195
[TBL] [Abstract][Full Text] [Related]
19. Role of the Histamine H
Schlicker E; Kathmann M
Handb Exp Pharmacol; 2017; 241():277-299. PubMed ID: 27787717
[TBL] [Abstract][Full Text] [Related]
20. The histamine H3 receptor as a therapeutic drug target for CNS disorders.
Gemkow MJ; Davenport AJ; Harich S; Ellenbroek BA; Cesura A; Hallett D
Drug Discov Today; 2009 May; 14(9-10):509-15. PubMed ID: 19429511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
